Trial Profile
A Phase Ib, Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Belvarafenib (Primary) ; Cobimetinib (Primary)
- Indications Biliary cancer; Bone metastases; Colorectal cancer; Glioblastoma; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 24 Oct 2023 Results (n=15) assessing activity and safety of Belva and Cobi in patients with BRAF fusion including presented at the 48th European Society for Medical Oncology Congress
- 27 Jul 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
- 27 Jul 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Jun 2024.